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Vitamin D is a hormone precursor with multiple biological effects. It binds 
to vitamin D receptors on target cells. It is an important participant in the 
metabolism of calcium and phosphorus in vivo. It is closely related to cell 
cycle, cell proliferation, differentiation, apoptosis, signal transduction and 
immune regulation. Its role in the treatment of infection, tumor and even 
immune diseases has been gradually recognized and studied. Patients with 
systemic lupus erythematosus generally have decreased levels of active 
vitamin D, and low levels of vitamin D are associated with disease oc-
currence, disease activity and complications. In the past ten years, a large 
number of studies have been carried out on it globally to explore the role of 
vitamin D in the occurrence and development of systemic lupus erythema-
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1. Introduction
Systemic lupus erythematosus (systemic lupus erythe-
matosus, SLE) is a connective tissue disease that is defi-
cient in the ability to clear the deposited immune complex, 
to the extent that it causes damage to multiple important 
organs such as the brain, kidney, and heart. The patho-
genesis is unclear, but it is generally believed that SLE 
pathogenesis is related to genetic, endocrine and environ-
mental factors [1]. Studies such as Muller showed for the 
first time that low vitamin D levels may be linked to SLE 
development in 1995[2] .Since then, the study on the rela-
tionship between the two has never been interrupted, from 
the regulation of peripheral bone metabolism mechanism 
to the regulation of cell pleiotropic regulation, especially 
after the discovery of the expression of vitamin D recep-
tor (vitamin D receptor, VDR) on the surface of immune 
cells, More studies on vitamin D and SLE immunomodu-
latory properties have been stimulated. Studies have con-
firmed that vitamin D deficiency in SLE patients is more 
obvious than in other immune diseases or healthy people, 
which may be related to light allergy and lack of light in 
SLE patients. And the use of glucocorticoids and other 
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drugs in the treatment process accelerated the loss of vi-
tamin D. Studies have also investigated differences in the 
prevalence of SLE races and regions, and found that the 
prevalence rate in high latitudes and non-white countries 
is higher, presumably because the vitamin D deficiency in 
these races is more significant, which is more likely to in-
duce SLE[3]. So far, a large number of studies have tried to 
explore the relationship between vitamin D deficiency and 
SLE disease pathogenesis, disease activity, organ injury 
and laboratory parameters, but the results are still incon-
clusive. This paper reviews the research progress of active 
vitamin D physiology, deficiency related diseases, clinical 
application and its relationship with SLE.
2. Physiology of Vitamin D, Disease Related 
to Deficiency and Clinical Application
2.1 The Production and Mechanism of Vitamin D 
The production and mechanism of vitamin D is a li-
posoluble ring-opening steroid. Its essence belongs to 
cholesterol. There are three main sources of production, 
namely, dietary source, skin production after sunlight 
exposure and drug supplement. Vitamin D in humans are 
synthesized mainly by skin exposure to ultraviolet light, 
while only a small fraction (<10%) is a dietary source[4].
Vitamin D mainly includes vitamin D2 and D3. Vitamin 
D2, also known as ergot calcitriol, is produced by ultravi-
olet radiation, mainly in yeast and plants. Vitamin D3, also 
known as cholecalciferol, is converted from 7-dehydro-
cholesterol in the skin after absorbing ultraviolet radiation. 
Vitamin D3 also comes from deep-sea fish oil and dairy 
products. The main source of human vitamin D is skin 
synthesis. Vitamin D2 and D3 are metabolized to form ac-
tive vitamins D： ossified triols (1,25-dihydroxyvitamin-D, 
1,25- (OH) 2-D)
[5-6].Vitamin D metabolism is a complex 
process, including ultraviolet radiation and hydroxylation, 
synthesis and catabolism. The process of forming active 
vitamin D requires one hydroxylation in the liver and one 
in the kidney, and finally the synthesis of 1,25-(OH)2-D 
in the kidney. 1, 25-(OH)2-D. In addition to kidney syn-
thesis, Extracrenal synthesis also exists in many tissues, 
Like parathyroid glands, keratinocytes and immune cells, 
etc. Synthetic active vitamins must be linked to vitamin 
D receptors (vitamin D receptor,); and VDR) only after 
binding can play biological activity. VDR are expressed 
in a variety of body tissues, including brain, heart, skin, 
gut, gonad, prostate, mammary gland, immune cells, as 
well as bone, intestine, R kidney and parathyroid gland. 
Many immune cells containing VDR include monocytes, 
macrophages, dendritic cells and activated T and B cells, 
And these immune cells also have hydroxylase (25-hy-
droxyvitamin D-1alpha hydroxylase,) in them CYP27B1), 
Precursor vitamin D converted into active vitamin D[7] . 
2.2 Vitamin D Deficiency Related Diseases
Vitamin D in addition to its classic function, the human 
body vitamin deficiency D also associated with many 
chronic diseases[5,6], These include immune diseases such 
as multiple sclerosis, rheumatoid arthritis, type 1 diabetes, 
inflammatory bowel disease, mixed connective tissue dis-
ease, autoimmune thyroid disease, scleroderma, systemic 
lupus erythematosus cardiovascular diseases such as cor-
onary heart disease, hypertension, heart failure, sudden 
cardiac death, malignant tumors such as colon cancer, 
breast cancer, non-Hodgkin lymphoma and neurological 
diseases such as Alzheimer’s disease[7,8].One Meta anal-
ysis suggests that lower and higher levels of 25-(OH)- D 
are associated with increased risk of disease mortality, and 
that ultraviolet radiation may affect many of the processes 
associated with vitamin D production in the body[2].As 
more and more research has been done on vitamin D in 
recent years, it has been found that it is more and more 
relevant to many diseases, especially in the field of im-
mune diseases. 
2.3 Clinical Application of Vitamin D 
Most of the active vitamin D drugs commonly used in 
clinic are the third generation new vitamin D analogues. 
They are widely used in osteoporosis, hyperparathyroid-
ism, chronic kidney disease, psoriasis and tumor.
3. Study on the Role of Vitamin D in SLE
3.1 Related Factors of Vitamin D Deficiency in 
SLE Patients 
Serum 25-(OH)- D levels were clinically used as crite-
ria for evaluating vitamin D levels in vivo. Studies have 
confirmed that levels of 25-(OH)-D in SLE patients are 
significantly inadequate or deficient, even if necessary 
vitamins are added D, this state of reduction or deficiency 
may still exist[9].The main reasons include the following. 
① Lack of light: time, season, latitude of residence, light 
allergy, age and other factors may lead to reduced skin 
reception of ultraviolet B, as a result, vitamin D synthesis 
is inadequate, A significant increase in the probability of 
SLE. ② Application of Glucocorticoids: This drug pro-
motes the metabolism of vitamin D, and so in the course 
of SLE treatment, A higher dose of vitamin D is needed 
to meet your balance. ③ Vitamin D activates and upreg-
ulates 24-hydroxylase to induce self-degradation, SLE 
activated B cells in patients upregulate the enzyme, the 
DOI: https://doi.org/10.30564/jams.v4i1.2728
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increase D vitamin degradation leads to its lack of [10]. 
④ SLE VDR gene polymorphism, anti-antibody produc-
tion, kidney damage, smoking, braking and other factors 
can also affect vitamin D levels and effects[11].
3.2 Relationship between VDR Gene Polymor-
phism and SLE Pathogenesis
The results of current research on the relationship 
between VDR gene polymorphisms and SLE risk, the 
difference of sample size, gene selection may lead to the 
emergence of different results. The results of a meta-anal-
ysis of VDR gene BsmI, FokI, ApaI or TaqI and the risk 
of SLE disease, BsmI B alleles are associated with SLE 
risk, FokI FF are susceptible genotypes of Asian SLE 
populations, FokI T /C and TaqI genetic polymorphisms 
were not associated with Caucasian disease, ApaI is not 
associated with SLE risk[12].Piantoni and other studies, The 
genotype appears more frequently ApaI AA SLE patients, 
Similar to Bb, BB BsmI B allele and FokI FF genotype, 
Also associated with SLE risk, ApaI AA, BsmI BB and 
FokI FF genotypes were also significantly associated with 
lupus nephritis and high activity of SLE diseases. Related 
studies have also found a significant correlation between 
Apa and BsmI gene polymorphisms, ApaAa-bb genotype 
was significantly associated with the onset of Han SLE in 
China, this genotype is mainly associated with polypluri-
sy, involvement of the blood system, and high titer anti-
body production[13-16].
3.3 Relationship between Active Vitamin D Level 
and SLE Disease Activity
Studies have shown a close relationship between low 
vitamin D levels and SLE disease activity[9,11,17]. Among 
them, Squance and other [18] found that patients with re-
duced or deficient vitamin D were more likely to express 
high titer anti-nuclear antibodies and anti-binary DNA an-
tibodies, the results suggest that vitamin D may be associ-
ated with the pathogenesis of SLE. Schoindre and other [19] 
studies SLE initial treatment of patients found, Patients 
with SLE disease activity score (SLEDAI score)≥6 had 
lower levels of vitamin D, The result has certain clinical 
significance; Besides, Sahebari and other [20] also show 
that, Vitamin D levels were negatively correlated with 
SLEDAI scores, and identified glucocorticoids and other 
drugs, obesity and kidney involvement as risk factors for 
further vitamin D deficiency in patients.Nevertheless, the 
SLEDAI score did not include smooth muscle involve-
ment and myocardial involvement in the scoring system, 
so McGhie and other [21] studied the relationship between 
vitamin D and the index score of British lupus assessment 
group. The results showed that low vitamin D level was 
negatively correlated with the score. AlSaleem and other [22] 
confirmed that vitamin D levels were negatively correlat-
ed with SLE disease activity, and given adequate vitamin 
D treatment in active children. The results showed that the 
disease activity decreased significantly and the renal and 
joint symptoms improved significantly. This conclusion 
is consistent with the results of cross-sectional studies in 
adults and young people [23-24].Combined with the above 
results, the mechanism mainly includes the following as-
pects: ① vitamin D can enhance cell chemotaxis, induce 
macrophage activation, inhibit dendritic cell maturation, 
and affect antigen presentation, attenuating helper T cells 
(T helper cell,); and Th11 and Th17 responses, Enhanced 
Th2 function, Promoting TGF β and forkhead transcrip-
tion factor gene expression through CC chemokine recep-
tor 4 expression, and increase the number T regulatory 
cells, Enhance its migration ability. But, uh, The balance 
in SLE patients with vitamin D deficiency is further dis-
rupted, To make interleukin 6,10, excessive secretion of 
cytokines such as tumor necrosis factor α, α interferon, 
To promote disease progression[13,25-26], Imbalance of cy-
tokine secretion mediates hyperactive B cells, Causing 
plasma cell differentiation to produce antibodies, Causes 
SLE multiple organs to be tired [27-29]. The study found, 
the disease activity of SLE patients with low vitamin D 
level was [30] with the expression of interferon in plasma. 
Aranow and other [31] have confirmed, Vitamin supple-
ments may D reduce the secretion of α interferon, Improv-
ing disease activity and laboratory indicators. ② Vitamin 
D can induce early apoptosis of activated B cells and de-
crease the function of B cells, while vitamin D deficiency 
causes excessive activity of B cells and increase the level 
of autoantibodies, which leads to the damage of multiple 
organs[10]. ③ Vitamin D inhibits apoptosis of mononu-
clear cells in peripheral blood by up-regulating the Bax, 
FasL expression of B cell lymphoma / leukemia gene and 
down-regulating the apoptosis related gene[25]. ④ Vitamin 
D deficiency is significantly associated with shortening 
of SLE telomeres, while previous studies have confirmed 
that SLE patients have shorter telomeres and higher activ-
ity of anti-terminal antibodies, suggesting that anti-termi-
nal antibodies are significantly associated with disease ac-
tivity in SLE patients[32].None of these studies confirmed 
SLE relationship between disease recurrence and vitamin 
D deficiency, which may be responsible for the short fol-
low-up period.
3.4 Relationship between Vitamin D Deficiency 
and SLE Complications 
Studies have shown that SLE patients with low vitamin 
DOI: https://doi.org/10.30564/jams.v4i1.2728
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D have a higher percentage of bone mineral content and a 
higher risk of fracture[33], The deficiency of active vitamin 
D in vivo destroys the bone metabolism balance between 
osteoblasts and osteoclasts, affects the secretion of osteo-
protegerin/nuclear factor kB receptor activator ligand and 
the establishment of bone transformation microenviron-
ment involved in it[34-36].Recently, it has been found that 
SLE mesenchymal stem cells have differentiation defects, 
which may be another cause of SLE related osteoporo-
sis[37], There is no correlation between active vitamin D 
and SLE defective mesenchymal stem cells. Low levels of 
vitamin D are associated with SLE with insulin resistance, 
dyslipidemia, cardiovascular risk and mental state, and re-
duced levels of vitamin D in non-diabetic patients increase 
insulin resistance and hyperlipidemia[38].Also, vitamin D 
can reduce cardiovascular risk by reducing the expres-
sion of chemokine ligand 10, improving endothelial cell 
function and repairing angiogenesis cells [39-41]. A study of 
neuropsychiatric lupus found that vitamin D deficiency is 
an important factor in sleep quality decline, fatigue and 
cognitive impairment[42-43].
3.5 Intervention Therapy for Vitamin D 
There are many studies on vitamin D intervention SLE 
at home and abroad, the differences of disease activity, 
inflammatory factors, autoantibodies and prognosis be-
fore and after vitamin D supplementation in SLE patients 
were compared. Research on vitamin D3 in SLE children 
with low vitamin D 2000U, 1 daily and 600 mg, calcium 
Two interventions per day, We found kidney damage three 
months later, SLEDAI scores and autoimmunity markers 
were improved[22].The findings are consistent with the 
findings of another cross-sectional study of young people 
and adults[44-45].Studies have shown that the combination 
of different doses of vitamin D in SLE patients can reduce 
the level of urine protein, the expression of interleukin-1, 
tumor necrosis factor α, anti- dsDNA antibody in serum, 
and reduce the disease activity of patients[11,17].Lima and 
other [46] conducted a 24-week randomized, double-blind, 
controlled trial of SLE patients with juvenile onset. the 
results showed that after the patients were treated with 
active vitamin D, the disease activity and fatigue score 
decreased compared with before treatment, and the symp-
toms of fatigue and fatigue were also improved. Never-
theless, a prospective study that treated premenopausal 
SLE patients with different vitamin D supplementation 
regimens found that although vitamin D levels were ele-
vated and the treatment was safe and effective, no signifi-
cant improvement in SLE disease activity and serological 
indicators was observed [47] either regimen.In addition, the 
following findings were found in the in vitro intervention 
test: ① The increase of CD T cell ratio in ① SLE patients 
can improve the degree of T cell dysfunction and cause 
phenotypic amplification. Active vitamin D may partici-
pate in the of immune tolerance mechanism of lympho-
cytes[48]. ② Vitamin D may be associated with a particular 
mode of cell death NETosis White blood cells isolated 
from peripheral blood were treated with different concen-
trations of vitamin D. The results showed that the number 
of early apoptosis of white blood cells in the treated sam-
ples was significantly reduced and the damage of endothe-
lial cells was reduced by NETosis methods[49]. ③ such as 
Wahono and Wu found that low active vitamin D levels 
affected dendritic cell maturation and Th17, regulatory 
cell activation. Treatment of isolated cultured peripheral 
blood monocytes and lymphocytes with different concen-
trations of active vitamin D, The results showed that the 
treated cells could slightly upregulate the β, of regulatory 
T cells and TGF and inhibit dendritic cell maturation and 
Th17 activation[51-52].
4. Conclusion
While there are many studies on the relationship be-
tween vitamin D and SLE, it is difficult for most studies to 
clarify the true significance of long-term vitamin D defi-
ciency in the process of SLE disease. While vitamin D, as 
an immunomodulator, can inhibit the secretion of inflam-
matory factors, reduce SLE antibody titer, reduce renal 
damage and reduce disease activity, and play a regulatory 
role in many immune pathways, the above effects are 
inevitably controversial. Moreover, in clinical work, the 
best time for vitamin D supplementation in SLE patients 
and the choice of supplementary dose are not clear, and 
more research is needed. Whether active vitamin D and 
its analogues can become the third kind of drugs to treat 
SLE or improve its complications in addition to hormones 
and immunosuppressants in the future will become a new 
direction for researchers to understand the mechanism of 
rheumatism and treat immune diseases.
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